Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Recommendation of “Hold” from Brokerages

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have earned an average rating of “Hold” from the four brokerages that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $5.08.

A number of research analysts have issued reports on MCRB shares. Chardan Capital reiterated a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research report on Wednesday, August 14th. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Thursday, October 24th. StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a research report on Friday, September 13th.

Seres Therapeutics Stock Performance

Shares of NASDAQ MCRB opened at $0.70 on Thursday. Seres Therapeutics has a 52 week low of $0.54 and a 52 week high of $2.05. The stock has a market capitalization of $106.01 million, a P/E ratio of -1.17 and a beta of 2.03. The stock’s fifty day moving average is $0.88 and its 200 day moving average is $0.92.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. During the same period in the prior year, the firm posted $0.36 earnings per share. Equities research analysts forecast that Seres Therapeutics will post -0.95 earnings per share for the current year.

Insider Activity

In other news, insider Teresa L. Young sold 24,480 shares of Seres Therapeutics stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $1.08, for a total transaction of $26,438.40. Following the sale, the insider now directly owns 78,178 shares of the company’s stock, valued at approximately $84,432.24. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders have sold 28,844 shares of company stock valued at $30,104. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Seres Therapeutics

Hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Seres Therapeutics during the first quarter valued at about $39,000. Providence Wealth Advisors LLC lifted its stake in shares of Seres Therapeutics by 49.5% in the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 25,250 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Seres Therapeutics in the second quarter worth approximately $64,000. Virtu Financial LLC acquired a new position in shares of Seres Therapeutics in the first quarter worth approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Seres Therapeutics in the second quarter worth approximately $92,000. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.